Citizens Financial Group Inc. RI Has $20.20 Million Stock Holdings in Stryker Co. (NYSE:SYK)

Citizens Financial Group Inc. RI increased its position in shares of Stryker Co. (NYSE:SYK) by 0.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,103 shares of the medical technology company’s stock after acquiring an additional 430 shares during the quarter. Citizens Financial Group Inc. RI’s holdings in Stryker were worth $20,200,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in SYK. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Stryker during the fourth quarter valued at $25,000. Dunhill Financial LLC lifted its stake in Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock valued at $27,000 after buying an additional 37 shares during the period. Centricity Wealth Management LLC acquired a new position in Stryker in the fourth quarter valued at about $30,000. BankPlus Trust Department acquired a new position in Stryker in the fourth quarter valued at about $33,000. Finally, Darwin Wealth Management LLC acquired a new position in Stryker in the third quarter valued at about $36,000. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analyst Ratings Changes

Several research firms have weighed in on SYK. Canaccord Genuity Group increased their target price on Stryker from $420.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 29th. Royal Bank of Canada increased their target price on Stryker from $425.00 to $435.00 and gave the company an “outperform” rating in a research note on Wednesday, January 29th. Barclays increased their target price on Stryker from $418.00 to $443.00 and gave the company an “overweight” rating in a research note on Monday, February 10th. Needham & Company LLC reaffirmed a “buy” rating and set a $442.00 price target on shares of Stryker in a research report on Wednesday, January 29th. Finally, StockNews.com lowered Stryker from a “buy” rating to a “hold” rating in a research report on Thursday, March 6th. Five analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $421.90.

Stryker Stock Down 2.7 %

SYK stock opened at $369.16 on Tuesday. The company has a quick ratio of 1.32, a current ratio of 1.95 and a debt-to-equity ratio of 0.59. The business has a 50 day moving average price of $382.59 and a two-hundred day moving average price of $373.31. The company has a market cap of $140.87 billion, a price-to-earnings ratio of 47.57, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a twelve month low of $314.93 and a twelve month high of $406.19.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period in the previous year, the business earned $3.46 earnings per share. Analysts anticipate that Stryker Co. will post 13.47 EPS for the current fiscal year.

Stryker Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.84 dividend. The ex-dividend date of this dividend is Monday, March 31st. This represents a $3.36 dividend on an annualized basis and a dividend yield of 0.91%. Stryker’s payout ratio is 43.30%.

Insider Activity

In other news, Director Allan C. Golston sold 2,458 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the completion of the sale, the director now directly owns 14,895 shares of the company’s stock, valued at $5,705,827.65. This trade represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, Director Ronda E. Stryker sold 201,392 shares of Stryker stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $392.24, for a total value of $78,993,998.08. Following the sale, the director now directly owns 3,642,075 shares of the company’s stock, valued at approximately $1,428,567,498. The trade was a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 5.90% of the company’s stock.

About Stryker

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.